Plasma Oligomeric Alpha-Synuclein Is Associated With Glucocerebrosidase Activity in Gaucher Disease

Movement Disorders

Volumn 30, Issue 7, 2015, Pages 989-991

  Nuzhnyi, Evgenii ^a   Emelyanov, Anton ^a,b,d   Boukina, Tatyana ^c   Usenko, Tatiana ^a,b   Yakimovskii, Andrey ^a   Zakharova, Ekaterina ^c   Pchelina, Sofya ^a,b,d  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

^c RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^d ST PETERSBURG ACADEMIC UNIVERSITY   (Russian Federation)

Author keywords

Alpha synuclein; Gaucher disease; Glucocerebrosidase; Oligomerization; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CHITOTRIOSIDASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; OLIGOMERIC ALPHA SYNUCLEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; FEMALE; GAUCHER DISEASE; GBA GENE; GENE; GENE MUTATION; HUMAN; LEUKOCYTE FUNCTION; MALE; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; BLOOD; INFANT; PRESCHOOL CHILD;

AGED; ALPHA-SYNUCLEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INFANT; MALE;

EID: 84931956998     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26200     Document Type: Article

References (14)

1. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
2. Emelyanov A, Boukina T, Yakimovskii A, et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia. Mov Disord 2012;27:158-159.
3. Pchelina SN, Nuzhnyi EP, Emelyanov AK, et al. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci Lett 2014;583C:188-193.
4. Argyriou A, Dermentzaki G, Papasilekas T, et al. Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci Lett 2012;528:205-209.
5. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-1190.
6. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
7. Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A 2013;110:3537-3542.
8. Parnetti L, Chiasserini D, Persichetti E, et al. Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. Mov Disord 2014;29:1019-1027.
9. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012;73:455-463.
10. Yap TL, Gruschus JM, Velayati A, et al. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011;286:28080-28088.
11. Campbell TN, Choy FY. Gaucher disease and the synucleinopathies: refining the relationship. Orphanet J Rare Dis 2012;7:12.
12. Zhang XK, Elbin CS, Chuang WL, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008;54:1725-1728.
13. Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord 2013;28:725-732.
14. Shachar T, Lo Bianco C, Recchia A, et al. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 2011;26:1593-1604.